

The 10th International Advanced Course on Vaccinology in Asia Pacific Regions

IVI, Seoul, May 10-15, 2010

DRAFT AGENDA

DAY 1: Monday, May 10, 2010

930 945 Welcome address and IVI introduction

M Favorov

EPIDEMIOLOGY

Chairperson:

945 1045 Vaccines and diseases control, elimination, and eradication

F Andre

TAB 1

1045 1100 Coffee break

1100 1130 Risks rates and measures of transmissibility

R Ochiai

TAB 2

1130 1200 Study designs for vaccine evaluation

S Grahek

TAB 3

1200 1300 Lunch

1300 1330 Surveillance: definition, goals and methodology

M Favorov

TAB 4

1330 1400 Ethical principles and review: the role of the IRB in the ethical review of vaccine clinical trials

H Kwon

TAB 5

IMMUNOBIOLOGY

Chairperson:

1400 1445 Vaccine concepts: immunological basis

C Czerkinsky

TAB 6

1445 1500 Coffee break

1500 1545 Basic principles of immune responses: innate versus adaptive immunity

H Kiyono

TAB 7

1545 1615 Immunological basis of mucosal vaccines

M Kweon

TAB 8

1700 1900 **Welcome reception**

at the IVI Lobby

DAY 2: Tuesday, May 11, 2010

MOVING FROM DISCOVERY TO LICENSED PRODUCT

Chairperson:

900 1000 Vaccine and Antigen delivery systems

M Liu

TAB 9

1000 1015 Coffee break

1015 1045 Role of regulatory agencies

G Smith

TAB 10

1045 1130 Development and GMP production of vaccines

R Carbis

TAB 11

1130 1230 Lunch

Chairperson:

1230 1400 New vaccine evaluation: phase I - III

J Clemens

TAB 12

1400 1415 Coffee break

1415 1500 Phase I-III pneumococcal conjugate clinical trials: case study

P Kilgore

TAB 13

1530 **Seoul sightseeing**

DAY 3: Wednesday, May 12, 2010

MOVING FROM LICENSING TO INTRODUCTION (1)

Chairperson:

900	1000	The changing regulatory environment: the rotavirus vaccine case	I Gust	TAB 14
1000	1030	Asian regulatory perspective and trends	S Cook	TAB 15
1030	1045	Coffee break		
1045	1130	AEFIs and risk communication	F Andre	TAB 16
1130	1300	Lunch		

MOVING FROM LICENSING TO INTRODUCTION (2)

Chairperson:

1300	1330	Phase 3B studies: demonstration projects	J Clemens	TAB 17
1330	1410	Population-based post-licensure surveillance	P Zuber	TAB 18
1410	1430	Coffee break		
1430	1500	Herd immunity conferred by vaccines	J Clemens	TAB 19
1500	1545	Special issues related to control of pandemic influenza vaccine	F Ahmed	TAB 20
1545	1630	Integration of immunisation and other health interventions in the health service context	NESI	TAB 21

DAY 4: Thursday, May 13, 2010

PRODUCT DEVELOPMENT PARTNERSHIPS

Chairperson:

900	940	Introductory lecture on PDP historical background and basic concepts	R Mahoney	TAB 22
940	1100	PDPs: models of accelerating the development and introduction of developing country vaccines with local producers/big pharma: Cholera Vaccines (40 mins) HIV Vaccines (40 mins)	R Cabris S Kochhar	TAB 23 TAB 24
1100	1115	Coffee break		
1115	1315	PDPs: models of accelerating the development and introduction of developing country vaccines with local producers/big pharma: HPV Vaccines (40 mins) Dengue Vaccines (40 mins) Typhoid Vaccines (40 mins)	C Llave B Letson S Shin	TAB 25 TAB 26 TAB 27
1315	1410	Lunch		
1410	1510	Technology transfer Technology transfer: an IVI perspective Development and technology transfer of cost-effective conjugate vaccine against <i>Haemophilus influenzae</i> type b	S Kothari M Beurret	TAB 28 TAB 29
1510	1525	Coffee break		
1525	1625	IVI laboratory tour		
1625		Group Photo		

DAY 5: Friday, May 14, 2010

MOVING FROM LICENSURE TO USE

Chairperson:

900	930	Evidence-based decision-making process for vaccine introduction	F Ahmed	TAB 30
930	1000	Health economics: principles and methods	B Maskery	TAB 31
1000	1015	Coffee break		

Introduction of new vaccines with emphasis in the Asia region:

1015	1045	Introduction of Hepatitis B vaccines in Asia	M Favorov	TAB 32
1045	1115	Hib vaccine introduction in the region	K Edmund	TAB 33
1115	1145	Rotavirus vaccine introduction	T Nelson	TAB 34
1145	1300	Lunch		

Programmatic Considerations:

1300	1330	Financing mechanisms for vaccines: an overview	A Levin	TAB 35
1330	1400	Financing mechanisms for GAVI eligible countries	A Levin	TAB 36
1400	1430	Development of investment case for cholera vaccines	B Maskery	TAB 37
1430	1530	Round table discussion	Chaired by TBA, F Andre, A Levin, F Ahmed, T Nelson, B Maskery	

1530	1545	Coffee break		
------	------	--------------	--	--

Chairperson:

1545	1630	Sharing experience: injection safety assessment and adverse event monitoring Discussion on participants' practical experiences	A Amarasinghe	TAB 38
------	------	---	---------------	--------

**Sharing experience: vaccine introduction in GAVI Programs
- cold chain, logistics**

1630	1700	WHO perspective	S Kone	TAB 39
1700	1730	Industry perspective	D Kohl	TAB 40
1730	1820	Discussion on participants' practical experiences		

DAY 6: Saturday, May 15, 2010

SPECIAL LECTURES

Chairperson: J Clemens

900	1030	Keynote closing speech - the future of vaccines and vaccination with special emphasis on avian flu and other pandemics	I Gust	TAB 41
1030	1100	Coffee break		
1100	1200	Closing ceremony	J Clemens	
1200	1400	Lunch		